Med BioGene Cuts Costs as Cash Dwindles

The firm, which has been unable to complete a US IPO, has cut staff, consultants, and its board of directors as it seeks funding and potential strategic alternatives.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.

Related Stories